Global Cancer Angiogenesis Pipeline Market
Share With :
The preceding decades have shown higher incidence and prevalence trends for cancer. Globally, the scenario is worsening with the mounting number of cancer patients every year. The number of new cancer cases is predicted to rise by 54% within the next two decades. In economically developing countries, adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, will gradually increase the burden of the treatment. This requirement has made cancer the most competitive and most studied arena.
Varied classes of chemotherapeutic products are available, ranging from monoclonal antibodies, vaccines, immunomodulators, and hormonal therapies to bispecific monoclonal antibodies. Raising the limitations of these therapies are that either they should be given in conjunction with other treatments, require a high dose or have got side effects and so on. Pharmacological parameters, overlapping boundaries, cost-effectiveness also are the significant limitations in these products.
One of the major segments of cancer therapy is occupied by angiogenesis inhibitors. Angiogenesis inhibitors are unique cancer-fighting agents because they block the growth of blood vessels that support tumor growth rather than blocking the growth of tumor cells themselves. Being a new targeted therapy, angiogenesis inhibitors have gained more focus and interest and have optimistic market opportunities. With the advent of new and improved technology, angiogenesis inhibitors therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (e.g., VEGF, PDGF, FGF, EGF), receptor tyrosine kinases, transcription factors such as HIF, as well as molecules involved in MAPK and PI3K signaling.
In some cancers, angiogenesis inhibitors appear to be most effective when combined with additional therapies. There are now several agents available in the market such as bevacizumab (Avastin™) that target the tumor vasculature through different pathways, either by inhibiting the formation of the tumor neovasculature or by directly targeting the mature tumor vessels. Because angiogenesis inhibitors work by slowing or stopping tumor growth without killing cancer cells, they are given over a long period.
Therapeutic innovations in various segments have made human acceptance of the new targeted therapies. Now, many of angiogenesis inhibitors are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. Although majorly angiogenesis inhibitors are used as supportive therapy rather than streamline drugs as they take huge time to even show reasonable results.
An extensive array of compounds is currently in pre-clinical development(Sonepcizumab/Pfizer, KER-1003/Keros, Beperminogene perplasmid/Anges), with many now in the clinic (RG7594/Roche-Phase 1, Darleukin/Philogen-Phase 2, Ofranergene obadenovec/ VBL Therapeutics-Phase 3) and/or achieving FDA approval.
Some of the key players include Acceleron Pharma, Advenchen Laboratories, Allergan, Alnylam Pharmaceuticals, Amgen, Biocon, Celgene, Five Prime Therapeutics, Fujifilm Kyowa Kirin Biologics, Roche, Novartis, Neumedicines, Onyx, Pfizer, TaiRx, TBG Diagnostics, XBiotech.
Hence, it is quite predictable that the global market for angiogenesis inhibitors for cancer treatment is expected to register a healthy annual market growth rate. The healthy growth rate can be related to the cumulative effects such as fast technological development, upsurge in the number of incidences of cancer patients, rise in the increasing adverse effects from chemotherapy, and increase in the prevalence of cancer patients around the globe.
Global Cancer Angiogenesis Pipeline Market Outlook (Revenue, US$ Mn, 2019 – 2030)
Global Cancer Angiogenesis Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.